We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Philips Shares AI Tool Data for Mitral Regurgitation Assessment at ESC
Read MoreHide Full Article
Key Takeaways
Philips' 3D Auto CFQ showed stronger agreement with cardiac MRI than the conventional 2D PISA method.
The AI tool recorded a 7-milliliter bias versus 14 milliliters for 2D PISA and a 0.77 volume correlation.
Philips says the technology could simplify assessment and monitoring of complex mitral regurgitation cases.
Koninklijke Philips (PHG - Free Report) shared preliminary clinical data at the European Society of Cardiology (ESC) Congress 2026 showing that its AI-powered 3D Auto CFQ (Color Flow Quantification) technology improved the assessment of mitral regurgitation compared with a conventional ultrasound-based method. The findings came from an ongoing international multicenter study using cardiac magnetic resonance imaging as the reference standard.
From an investor's perspective, the update reinforces Philips' strategy of expanding AI-enabled ultrasound capabilities in cardiology, a key growth area within its Image Guided Therapy and Diagnostic businesses. Stronger clinical validation at a major medical conference could support broader physician adoption, strengthen the company's competitive position in cardiovascular imaging and create long-term opportunities as hospitals increasingly seek AI-driven workflow and diagnostic tools.
Likely Trend of PHG Stock Following the News
Following the announcement, shares of PHG traded flat yesterday. Year to date, shares of the company have lost 3.8% compared with the industry’s 16.6% decline. However, the S&P 500 has risen 11.4% in the same timeframe.
The ESC Congress 2026 clinical validation strengthens Philips' long-term growth prospects by reinforcing the clinical credibility of its AI-powered cardiovascular ultrasound portfolio in a large and growing structural heart disease market. Preliminary data showing closer agreement with cardiac MRI than the conventional 2D PISA method could support broader physician adoption, help differentiate Philips' premium ultrasound platforms and expand software-driven revenue opportunities over time.
As hospitals increasingly prioritize AI-enabled diagnostic accuracy and workflow efficiency, stronger clinical evidence from a major cardiology conference may enhance Philips' competitive position and support sustained demand for its imaging solutions.
PHG currently has a market capitalization of $25.92 billion.
Image Source: Zacks Investment Research
More on the News
Mitral regurgitation is among the most common heart valve disorders worldwide, making accurate disease severity assessment critical for treatment planning. The guideline-recommended 2D PISA method relies on geometric assumptions and single-frame measurements, which can reduce accuracy in patients with multiple or eccentric regurgitant jets. Philips' AI-powered 3D Auto CFQ addresses these limitations by using 3D transesophageal echocardiography to reconstruct and continuously track the regurgitant convergence zone throughout systole, while accounting for changes in the regurgitant orifice area and multiple regurgitant jets to deliver a more comprehensive assessment of regurgitant volume.
The clinical findings came from an ongoing prospective, observational, multicenter international study comparing Philips' 3D Auto CFQ with the conventional 2D PISA approach using cardiac magnetic resonance imaging (CMR) as the reference standard. Preliminary results showed that 3D Auto CFQ generated lower mitral regurgitant volume measurements and demonstrated stronger agreement with CMR than the conventional method. The technology recorded a bias of 7 milliliters compared with 14 milliliters for 2D PISA and achieved a regurgitant volume correlation of 0.77, while investigators also evaluated severity reclassification between the two approaches for the first time.
The late-breaking data were presented at the ESC Congress 2026 by investigators led by Carlo Federico Guarino of Hospital University Germans Trias i Pujol in Spain. According to study collaborator Victoria Delgado, conventional methods have well-recognized limitations, while the new findings indicate that AI-powered 3D Auto CFQ could help clinicians more consistently quantify mitral regurgitation across a broader range of disease presentations. Philips believes the ultrasound-based technology could simplify patient assessment and longitudinal monitoring, enabling more timely clinical decisions in complex cases where conventional evaluation has been more challenging.
Industry Prospects Favoring the Market
According to the data provided by Fortune Business Insights, the global echocardiography market size was valued at $2.13 billion in 2025 and is projected to grow from $2.29 billion in 2026 to $4.07 billion by 2034, exhibiting a CAGR of 7.45%.
Growth in the forecast period can be attributed to the rising prevalence of heart-related disorders, demand for non-invasive procedures and the high efficiency associated with an echocardiogram.
Other News
Recently, PHG announced that its EU-backed COMBINE-CT project has advanced from technology development to clinical validation, marking a key milestone in its AI-enabled cardiac imaging strategy. The four-year initiative, launched in 2023, has begun five multicenter clinical studies to evaluate an integrated CT-based care pathway for coronary artery disease, using AI-powered CT and Spectral CT imaging to support diagnosis, treatment planning, procedure guidance and follow-up care.
PHG’s Zacks Rank & Key Picks
Currently, PHG has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
View the Zacks #1 Rank List
Image: Bigstock
Philips Shares AI Tool Data for Mitral Regurgitation Assessment at ESC
Key Takeaways
Koninklijke Philips (PHG - Free Report) shared preliminary clinical data at the European Society of Cardiology (ESC) Congress 2026 showing that its AI-powered 3D Auto CFQ (Color Flow Quantification) technology improved the assessment of mitral regurgitation compared with a conventional ultrasound-based method. The findings came from an ongoing international multicenter study using cardiac magnetic resonance imaging as the reference standard.
From an investor's perspective, the update reinforces Philips' strategy of expanding AI-enabled ultrasound capabilities in cardiology, a key growth area within its Image Guided Therapy and Diagnostic businesses. Stronger clinical validation at a major medical conference could support broader physician adoption, strengthen the company's competitive position in cardiovascular imaging and create long-term opportunities as hospitals increasingly seek AI-driven workflow and diagnostic tools.
Likely Trend of PHG Stock Following the News
Following the announcement, shares of PHG traded flat yesterday. Year to date, shares of the company have lost 3.8% compared with the industry’s 16.6% decline. However, the S&P 500 has risen 11.4% in the same timeframe.
The ESC Congress 2026 clinical validation strengthens Philips' long-term growth prospects by reinforcing the clinical credibility of its AI-powered cardiovascular ultrasound portfolio in a large and growing structural heart disease market. Preliminary data showing closer agreement with cardiac MRI than the conventional 2D PISA method could support broader physician adoption, help differentiate Philips' premium ultrasound platforms and expand software-driven revenue opportunities over time.
As hospitals increasingly prioritize AI-enabled diagnostic accuracy and workflow efficiency, stronger clinical evidence from a major cardiology conference may enhance Philips' competitive position and support sustained demand for its imaging solutions.
PHG currently has a market capitalization of $25.92 billion.
Image Source: Zacks Investment Research
More on the News
Mitral regurgitation is among the most common heart valve disorders worldwide, making accurate disease severity assessment critical for treatment planning. The guideline-recommended 2D PISA method relies on geometric assumptions and single-frame measurements, which can reduce accuracy in patients with multiple or eccentric regurgitant jets. Philips' AI-powered 3D Auto CFQ addresses these limitations by using 3D transesophageal echocardiography to reconstruct and continuously track the regurgitant convergence zone throughout systole, while accounting for changes in the regurgitant orifice area and multiple regurgitant jets to deliver a more comprehensive assessment of regurgitant volume.
The clinical findings came from an ongoing prospective, observational, multicenter international study comparing Philips' 3D Auto CFQ with the conventional 2D PISA approach using cardiac magnetic resonance imaging (CMR) as the reference standard. Preliminary results showed that 3D Auto CFQ generated lower mitral regurgitant volume measurements and demonstrated stronger agreement with CMR than the conventional method. The technology recorded a bias of 7 milliliters compared with 14 milliliters for 2D PISA and achieved a regurgitant volume correlation of 0.77, while investigators also evaluated severity reclassification between the two approaches for the first time.
The late-breaking data were presented at the ESC Congress 2026 by investigators led by Carlo Federico Guarino of Hospital University Germans Trias i Pujol in Spain. According to study collaborator Victoria Delgado, conventional methods have well-recognized limitations, while the new findings indicate that AI-powered 3D Auto CFQ could help clinicians more consistently quantify mitral regurgitation across a broader range of disease presentations. Philips believes the ultrasound-based technology could simplify patient assessment and longitudinal monitoring, enabling more timely clinical decisions in complex cases where conventional evaluation has been more challenging.
Industry Prospects Favoring the Market
According to the data provided by Fortune Business Insights, the global echocardiography market size was valued at $2.13 billion in 2025 and is projected to grow from $2.29 billion in 2026 to $4.07 billion by 2034, exhibiting a CAGR of 7.45%.
Growth in the forecast period can be attributed to the rising prevalence of heart-related disorders, demand for non-invasive procedures and the high efficiency associated with an echocardiogram.
Other News
Recently, PHG announced that its EU-backed COMBINE-CT project has advanced from technology development to clinical validation, marking a key milestone in its AI-enabled cardiac imaging strategy. The four-year initiative, launched in 2023, has begun five multicenter clinical studies to evaluate an integrated CT-based care pathway for coronary artery disease, using AI-powered CT and Spectral CT imaging to support diagnosis, treatment planning, procedure guidance and follow-up care.
PHG’s Zacks Rank & Key Picks
Currently, PHG has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.